Intel’s 18A-P Milestone Fails to Stem Weekly Slide as Earnings Test Looms

Intel’s stock is suffering its worst week in months, even as the chipmaker crosses a critical technical threshold in its foundry turnaround. Shares slipped 2.23 percent on Friday to close at €96.26, capping a weekly loss of 11.77 percent that has pushed the equity 22.73 percent below its 52-week high of €124.58 reached in late June. The 50-day moving average of €102.84 now sits above the current price, and the relative strength index of 42.9 points to a consolidation phase rather than an oversold condition.

The pullback clips a blistering rally that has seen Intel’s stock surge 186.45 percent since January and 372.67 percent over the past twelve months. From the 52-week trough of €16.69, shares have rocketed 476.82 percent, valuing the company at roughly €483.49 billion. The annualized volatility over the last 30 days stands at 91.61 percent, underscoring the high-octane trading that has accompanied Intel’s strategic pivot.

Foundry Progress Advances Behind the Scenes

While traders take profits, Intel’s engineering teams are hitting milestones. The company confirmed in mid-June that the enhanced 18A-P manufacturing process has entered risk production. This performance-boosted variant of the baseline 18A node promises either nine percent more compute power or 18 percent lower power consumption — a crucial offering for prospective external foundry customers. Reports indicate that initial yield issues on the original 18A process have largely been resolved, with current production capacity reaching approximately 30,000 wafers per month.

The move into risk production marks a pivotal step in Intel’s “IDM 2.0” strategy, signalling to potential clients that the technology is nearing volume manufacturing. For investors, the foundry ramp remains the single most important driver of the long-term narrative, but the near-term stock price is increasingly sensitive to execution updates.

Institutional Investors Rotate Positions

Regulatory filings from the first half of July reveal a mixed picture among large shareholders. Accredited Investors Inc. slashed its Intel stake by a hefty 47.6 percent, while 180 Wealth Advisors LLC sold roughly 14,414 shares, reducing its position by 12.9 percent. Yet the institutional backbone appears resilient — hedge funds and big investors collectively still control about 64.53 percent of outstanding shares. Some players have taken advantage of the volatility to add exposure: Regent Peak Wealth Advisors LLC boosted its holdings by 13.8 percent.

These shifts occur as the market weighs Intel’s aggressive capital spending against the long-term promise of its foundry roadmap. The rebalancing among institutional accounts suggests no uniform view on whether the stock’s meteoric rise has further to run.

Should investors sell immediately? Or is it worth buying Intel?

Analyst Community Splits Ahead of Q2 Report

Wall Street’s opinion on Intel is sharply divided heading into earnings. Stifel analyst Ruben Roy raised his price target from $75 to $120 on July 10, while keeping a Hold rating. Roy argues that near-term stock movement will hinge on server CPU demand signals and graphics chip delivery capability, with average selling prices and volumes for server processors being the key metrics to watch.

Wells Fargo’s Aaron Rakers takes a more cautious stance, holding a neutral rating with a $110 price target — just 0.78 percent above the current level. Rakers nonetheless expects a “strong server CPU update” and highlights several milestones for the foundry division: the 18A ramp for Panther Lake chips, the pull-forward of Coral Rapids to mid-2027, and the waning priority of Diamond Rapids. He also stresses that the real test for the foundry business is landing external customers, with the release of the 14A PDK v0.9 in the autumn seen as a “critical milestone” — though risk production for 14A remains a 2028 story.

The broader analyst consensus lands at Hold, with an average price target of $97.88. Out of 49 analysts, two rate the stock Strong Buy, 15 say Buy, 28 recommend Hold, and four issue Sell. Other notable moves include Morgan Stanley’s June downgrade from Overweight to Underweight, Barclays raising its target from $65 to $100 with a neutral rating, and Oppenheimer initiating coverage with an Outperform.

Earnings Day: The Real Verdict

Intel will report second-quarter 2026 results on Thursday, July 23, after the market close. Consensus estimates call for earnings per share of $0.19 on revenue of $14.40 billion. The earnings call is expected to focus on two fronts: the pace of the foundry ramp and pricing trends in the core processor business.

The wide gap between the Stifel and Wells Fargo targets — $120 versus $110 — illustrates just how much hangs on management commentary. With the stock trading 22 percent off its high and volatility still elevated, the upcoming quarterly report will either justify the pullback as a healthy consolidation or confirm that the market’s enthusiasm ran ahead of the numbers.